Loading...
机构名称:
¥ 3.0

Evidence from 1 ongoing phase I/II open-label, single-arm study (EPCORE NHL-1, which included 157 patients with r/r LBCL) suggested that treatment with epcoritamab may result in clinically meaningful improvements in median overall survival (OS) (OS = 18.5 months; 95% confidence interval [CI], 11.7 to |||| ) and progression-free survival (PFS) (PFS = 4.4个月; 95%CI,3.0至8.8)。在12个月时对OS和PFS进行其他里程碑分析|||| |||||| ||| ||||||和18个月|||| |||||| ||| ||||||支持生存分析。epcoritamab与|||||的临床有意义的完整响应(CR)相关联||| ||| ||| || |||||和持久的响应(响应的中值持续时间[dor] = ||| ||||||; 95%CI,9.7 to |||||)。EPCORE NHL-1研究的结果表明,与健康相关的生活质量(HRQOL)没有损害。

epcoritamab(epkinly)

epcoritamab(epkinly)PDF文件第1页

epcoritamab(epkinly)PDF文件第2页

epcoritamab(epkinly)PDF文件第3页

epcoritamab(epkinly)PDF文件第4页

epcoritamab(epkinly)PDF文件第5页